ARCHIVES

Merck Serono Cancels Tecemotide Program In NSCLC, Including Two Phase III Trials

This article is from The Cancer Letter archive.

Vol. 37 No. 9 | September 26, 2014

Download PDF Visit The Full Archive

Related Articles

Gore Proposes New War On cancer, Double research Funding Over 5 years

July 9, 1999

NIH Advisors Suggest Revamping Grant Application Review

June 14, 1996

Also Anna Barker gets new, longer title at NCI; Mark Clanton named deputy director for care, delivery.

February 13, 2004

ASCO Honors Eight With Special Awards

May 24, 2002

Major Changes Being Considered By NCI For FCRA

April 14, 1978

NCI Director Defends Goal to Eliminate Suffering, Death From Cancer by 2015

June 13, 2003